Tirzepatide trial comparisons
A molecule with combined hormone activity has been tested directly against another medicine. Those comparisons give the combination discussion something solid to work with.
The semaglutide comparison in obesity
The 2025 SURMOUNT-5 trial randomized 751 adults with obesity, without type 2 diabetes, to tirzepatide or semaglutide. At 72 weeks, least-squares mean weight change was -20.2% with tirzepatide and -13.7% with semaglutide. Participants and investigators knew which treatment was assigned: this was an open-label trial.
Both groups received the maximum trial dose they could tolerate. The comparison therefore concerns the treatments as studied, including their dose ranges and tolerability. It cannot assign a share of the weight difference to each hormone receptor.
I regard a direct comparison like this as much more persuasive than setting percentages from unrelated trials next to one another. The participants faced the same study design and follow-up. That is a meaningful answer to a defined question.
The diabetes comparison
An earlier direct trial, SURPASS-2, enrolled 1,879 adults with type 2 diabetes and followed them for 40 weeks. Tirzepatide produced greater reductions in glycated haemoglobin and body weight than semaglutide at the comparator dose studied.
Glycated haemoglobin, usually written HbA1c, reflects blood-sugar exposure over time. Here the investigators were asking a diabetes-treatment question as well as a weight question. The obesity and diabetes comparisons belong alongside one another, with their different populations left visible.
The placebo-controlled SURMOUNT-1 trial studied 2,539 adults with obesity or overweight plus a weight-related complication, without diabetes, over 72 weeks. It established substantial weight reductions and documented gastrointestinal adverse effects, chiefly mild to moderate and concentrated during dose escalation.
GIP and GLP-1 in a single molecule
Tirzepatide is a 39-amino-acid peptide that activates receptors for GIP and GLP-1, gut hormones involved in meal-related insulin release. It also reduces appetite, suppresses glucagon and delays stomach emptying. A fatty attachment promotes binding to a blood protein, helping the drug remain in circulation longer.
The 2018 development paper included cell work, mice and an early human programme involving 142 people. In mice, combined receptor action reduced food intake and body weight more than selective GLP-1 activity. The early human work supported further development; the large clinical comparisons came later.
The 2020 receptor experiments found stronger engagement of GIP receptors than GLP-1 receptors and a particular pattern of GLP-1 signalling. These were laboratory and islet experiments. I take their complexity as a warning against the appealing idea that “two hormones” means two equal contributions.
A purpose-built molecule tested through this sequence is a useful example of combined action. It provides no evidence that adding MOTS-c produces another clinical gain.
Tirzepatide adverse effects
Gastrointestinal problems—nausea, vomiting, diarrhea and constipation—are the most common adverse effects and can lead to treatment stopping. The obesity trial documented these effects alongside the weight results.
A review of nine randomized trials with 9,871 participants found an increased combined outcome of gallbladder or biliary disease. Individual components did not each show a significant increase. Pancreatitis showed no statistically significant increase in that analysis, while the uncertainty allowed by the results still leaves it a monitored concern.
The clinical reference and prescribing cautions include a boxed warning based on thyroid C-cell tumours in rodents; whether the risk applies to humans is unestablished. A personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia type 2, rules out treatment. Combining tirzepatide with insulin or medicines that stimulate insulin release can increase hypoglycaemia risk.
Delayed stomach emptying can affect oral medicines, including the reliability of oral hormonal contraception when treatment begins or the dose increases. Retained stomach contents also matter around anesthesia and procedures, even after fasting. Lost weight includes lean tissue as well as fat, and weight regain after stopping remains a concern in the wider gut-hormone treatment literature.
I object when combination arithmetic counts an extra hoped-for benefit while leaving these existing cautions off the page.
Food thoughts, anecdotes and approved uses
People describe quieter thoughts about food, more energy, altered tastes, digestive problems and hair shedding in community discussions and interviews. These are anecdotal accounts, not clinical evidence of how often a benefit or harm occurs or what caused it. I miss those ordinary particulars in an average weight change. A report about a mixture introduces even more uncertainty about which ingredient did what.
Tirzepatide received FDA approval for type 2 diabetes in May 2022. Chronic weight management approval followed in November 2023 for adults with obesity or overweight plus a weight-related condition. Approval also covers moderate-to-severe obstructive sleep apnea in adults with obesity. Approved formulations require a prescription. The reference chapter records the earlier diabetes indication; its historical description of weight use predates the separate weight-management approval.
The comparison page places these clinical trials beside tesamorelin and MOTS-c without creating a head-to-head result that never happened in those studies.